PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug

For more than a decade, PTC Therapeutics has been going back and forth with the FDA to find a path forward for a Duchenne muscular dystrophy drug with spotty track record in clinical testing. That effort has come to an end. PTC has withdrawn its application seeking regulatory approval for the drug ataluren, brand name […]